Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Botulinum Toxin For The Treatment Of Essential Blepharospasm.

J. Shore, C. R. Leone, P. S. O'Connor, R. W. Neuhaus, A. C. Arnold
Published 1986 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Twenty-six patients with essential blepharospasm were treated with botulinum toxin by injection. The onset of protractor weakness in all patients ranged from one to five days following treatment. Maximal weakness developed within 12 days. There was a variable and gradual return of protractor strength over eight to 29 weeks in most patients and, with it, a return of spasm. Twenty-five patients received some degree of functional relief following initial injection. In most patients, however, the post-injection result could not be stabilized and repeat injections have been necessary to control recurrent spasms. There was one treatment failure. Three patients treated by injection following previous neurectomy and myectomy appeared to have a reduced requirement for subsequent injections. Complications included transient ptosis in six patients and mild exposure symptoms in four patients. Extraocular muscle paresis did not occur. There were no systemic side effects from the botulinum toxin injections.



This paper is referenced by
10.3109/08820539209065092
Botulinum toxin in ophthalmology
J. Holmes (1992)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1007/s00702-010-0546-9
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm
B. Wabbels (2010)
10.1016/B978-0-12-644445-2.50026-X
CHAPTER 18 – Clostridial Toxins as Therapeutic Agents
A. B. Scott (1989)
10.1001/ARCHOTOL.1988.01860240057024
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
A. W. Biglan (1988)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.1136/BJO.75.12.737
Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years.
J. Mauriello (1991)
Transient Cortical Blindness Due to Hypertensive Encephalopathy: Magnetic Resonance Imaging Correlation
S. Erzurum ()
10.1212/WNL.40.9.1332
Assessment
(1990)
10.1016/S0025-6196(12)64977-5
Treatment of blepharospasm with botulinum toxin.
R. H. Kennedy (1989)
10.1016/0039-6257(89)90040-4
Essential blepharospasm and related dystonias.
D. Jordan (1989)
10.1016/S0008-4182(01)80084-3
Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time.
G. Drummond (2001)
10.1136/bjo.75.8.487
Surgical management of essential blepharospasm.
A. Bates (1991)
10.1212/01.WNL.0000103444.45882.D8
Ophthalmologic features of Parkinson’s disease
V. Biousse (2004)
10.1016/S0039-6257(97)81995-9
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
J. Dutton (1996)
Semantic Scholar Logo Some data provided by SemanticScholar